A made-to-order DNA vaccine takes aim at liver cancer's return
NCT ID NCT07722741
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This phase II trial tests whether a personalized DNA vaccine, tailored to each patient's tumor, can keep high-risk liver cancer from coming back after surgical removal. Participants who have no remaining signs of cancer after surgery will receive the vaccine plus an immune booster, or simply be monitored. The goal is to see if the vaccine can train the immune system to recognize and destroy any leftover cancer cells, potentially extending the time without recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a personalized neoantigen DNA vaccine (GNOS-PV02) plus a plasmid encoding IL-12 (INO-9012), delivered by injection followed by electroporation
- What this could lead to
- If successful, this approach could offer a way to prevent liver cancer from coming back after surgery, potentially improving long-term survival.
- What could go wrong
- This is an early-phase trial with only 90 participants, so results may not apply broadly. The vaccine is personalized, making it complex and costly to produce, and side effects from the vaccine or electroporation are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Simple blood test aims to catch liver cancer before It's too late
- Engineered virus takes on liver cancer when standard treatment fails
- Ultrasound vs. MRI: which spots hidden liver cancer better?
- Epigenetic drug may re-sensitize liver tumors to immunotherapy
- New hope for liver cancer patients who failed immunotherapy?
- New cocktail of drugs and targeted procedure aims to control liver cancer